Identification of putative biomarkers for HIV-associated neurocognitive impairment in the CSF of HIV-infected patients under cART therapy determined by mass spectrometry.
about
Proteomics, biomarkers, and HIV-1: A current perspectiveUnderstanding the MIND phenotype: macrophage/microglia inflammation in neurocognitive disorders related to human immunodeficiency virus infection.Investigating the biology of alpha herpesviruses with MS-based proteomicsMass spectrometric phosphoproteome analysis of HIV-infected brain reveals novel phosphorylation sites and differential phosphorylation patterns.Proteomic and other mass spectrometry based "omics" biomarker discovery and validation in pediatric venous thromboembolism and arterial ischemic stroke: current state, unmet needs, and future directions.Insights into the human brain proteome: Disclosing the biological meaning of protein networks in cerebrospinal fluid.Quantitative Proteomics of Vestibular Schwannoma Cerebrospinal Fluid: A Pilot Study.Childhood maltreatment and HIV-associated neurocognitive disorders share similar pathophysiology: a potential sensitisation mechanism?Variability in C-reactive protein is associated with cognitive impairment in women living with and without HIV: a longitudinal study.HIV as a Cause of Immune Activation and Immunosenescence.ORM Elevation in Response to Cognitive Impairment Is an Accompanying Phenomenon.
P2860
Q26853681-D0CFD4C5-4393-44C6-B0B8-438EB42A675BQ35264787-5ED83DFD-A7B0-4AC6-8011-DE6159B3634CQ35786606-66A6F4FB-3487-4DA7-ABCB-CBF024034220Q37401992-35D0DA81-D8EC-4AA6-A9C9-03961003379FQ38266067-2E0EA2B9-1E70-4DF3-886E-3D4796C66A56Q38844925-F0950612-F81B-48BB-A86B-BB0CE8B0E766Q38901196-1F5F6A0E-090F-4F96-84B1-635848524F75Q39417239-7075FEC7-1099-45FE-9223-2B7BC7A8FD89Q46319672-6A71C68E-8E18-47F0-8B10-430AE09A0855Q47151081-C00DB536-5737-44D0-A49F-948AA08F1339Q50500056-37A94AF7-D7A3-41AD-B688-644FDE35BC8C
P2860
Identification of putative biomarkers for HIV-associated neurocognitive impairment in the CSF of HIV-infected patients under cART therapy determined by mass spectrometry.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Identification of putative bio ...... termined by mass spectrometry.
@ast
Identification of putative bio ...... termined by mass spectrometry.
@en
type
label
Identification of putative bio ...... termined by mass spectrometry.
@ast
Identification of putative bio ...... termined by mass spectrometry.
@en
prefLabel
Identification of putative bio ...... termined by mass spectrometry.
@ast
Identification of putative bio ...... termined by mass spectrometry.
@en
P2093
P2860
P50
P1476
Identification of putative bio ...... termined by mass spectrometry.
@en
P2093
Adriana Bora
Avindra Nath
David R Graham
Justin C McArthur
Norman Haughey
Raghothama Chaerkady
Richard Moxley
Robert Cotter
P2860
P2888
P304
P356
10.1007/S13365-014-0263-5
P577
2014-07-24T00:00:00Z